These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31376566)

  • 1. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
    Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Yang L; Zhou F; Zhuang Y; Liu Y; Xu L; Zhao H; Xiang Y; Dai X; Liu Z; Huang X; Wang L; Zhao C
    Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
    Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
    Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel CDK9 inhibitor with tridentate ligand: Design, synthesis and biological evaluation.
    Zhong Y; Xu J; Ding S; Cao H; Zhang Y; Hu B; Han S; Yang H; Cheng M; Li J; Sun Y; Liu Y
    Bioorg Chem; 2024 Sep; 150():107550. PubMed ID: 38878756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
    Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
    Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
    Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
    Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
    Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
    Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
    Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
    Alsfouk A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
    Wang X; Chen F; Gou S
    Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.
    Bistrović A; Krstulović L; Harej A; Grbčić P; Sedić M; Koštrun S; Pavelić SK; Bajić M; Raić-Malić S
    Eur J Med Chem; 2018 Jan; 143():1616-1634. PubMed ID: 29133046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
    Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
    Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
    He L; Li D; Zhang C; Bai P; Chen L
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4171-4175. PubMed ID: 28734581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
    Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
    J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
    Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC.
    Wang X; Lu Y; Chen S; Zhu Z; Fu Y; Zhang J; He J; Huang L; Luo L; Guo W; Xu Z; Xie Z; Xu X; Zhang Y; Ye F; Ma S
    Bioorg Chem; 2024 Aug; 149():107500. PubMed ID: 38823310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.